News

Find out what the GMP Auditor Association was working on and accomplished in the first four months of 2025 - in the latest report.

More

In May 2025, the IPEC (International Pharmaceutical Excipients Council Europe (IPEC Europe) asbl) announced the new Version 1 of its “IPEC Risk Assessment Guide for Pharmaceutical Excipients - Risk Assessment for Excipient Manufacturers (Version 1, 2025)” on its website.

More

A recent FDA Warning Letter reveals severe GMP breaches at a U.S. drug manufacturer, including the absence of written procedures, reliance on undocumented processes, and a failure to perform basic analytical testing such as identity, strength, and microbiological checks prior to product release.

More

The FDA inspection of the US manufacturer of OTC products already took place in January 2025. The FDA criticized laboratory tests, missing microbiological specifications and the Quality Unit, which had not fulfilled its responsibilities. The water system in particular also showed serious deficiencies. Read more.

More

The Q&A document "Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products", which was prepared jointly by the EMA and the CMDh, has been updated once again and published in the new revision 22 on the EMA website.

More

A US company received a Warning Letter because of problems at their CMO. FDA points out that companies should have a robust qualification process for CMOs.

More

The guideline 'Additional guidance on the assessment on the risk assessment for presence of N-nitrosamines in APIs', first published in February 2020, has now been revised by a subgroup of the 'APIC Nitrosamines Task Force' and recently published in its latest version on the APIC website. The document is now called 'Nitrosamine Risk Management: Guidance for API Manufacturers' and has been extensively updated.

More

A Warning Letter was issued to a Dutch company, also because root cause determinations and CAPAs were deemed inadequate.

More

The FDA found serious GMP deficiencies during an inspection of a Chinese pharmaceutical manufacturer in November 2024. These include, above all, inadequate hygiene and ensuring the sterility of the products. For example, medicinal products were labelled as 'sterile' although neither sterilisation nor sterility tests were carried out.

More

The draft guideline "STABILITY TESTING OF DRUG SUBSTANCES AND DRUG PRODUCTS" of the ICH was published in April 2025 and is now available for public comment.

More
x